Skip to content

Semaglutide improves metabolic and histological outcomes and reverses clinically relevant biomarker alterations in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

  • Barbora Krajnikova

Background & aim: The long-acting glucagon-like peptide-1 (GLP1) receptor agonist semaglutide was recently approved as the first GLP-1–based therapy for people with MASH and moderate-to-severe fibrosis. Clinical studies have demonstrated that semaglutide not only improves liver histology but also reverses…

Read more

Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model

  • Henrik

Background & aim: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as promising therapeutic candidates for metabolic dysfunction-associated steatohepatitis (MASH). Importantly, semaglutide was recently approved as the first GLP-1-based treatment for people with MASH with moderate-to-severe fibrosis. Translational models that recapitulate…

Read more

Quantitative Characterization of a Dihydrotestosterone-Induced Mouse Model of Polycystic Ovary Syndrome Using Whole-Ovary 3D Imaging and Metabolic Profiling

  • Allison Butt

Background & aim: Polycystic ovary syndrome (PCOS) affects approximately 10–15% of women of reproductive age and is a leading cause of anovulation and infertility. PCOS is frequently accompanied by hyperandrogenism, insulin resistance, and altered body composition. Androgen-induced mouse models reproduce…

Read more
Back To Top